The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease

被引：15

作者：

Tousi, B

Subramanian, T

机构：

[1] Cleveland Clin Fdn, Lerner Res Inst, Dept Neurol, Cleveland, OH 44195 USA

[2] Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA

[3] Cleveland Clin Fdn, Lerner Res Inst, Dept Phys Med & Rehabil, Cleveland, OH 44195 USA

[4] Cleveland Clin Fdn, Ctr Neurol Restorat, Cleveland, OH 44195 USA

来源：

PARKINSONISM & RELATED DISORDERS | 2005年 / 11卷 / 05期

关键词：

dyskinesia; Parkinson's disease; levetiracetam; levodopa-induced dyskinesia;

D O I：

10.1016/j.parkreldis.2004.11.003

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：333 / 334

页数：2

共 7 条

[1] Levedracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque [J].

Bezard, E ;

Hill, MP ;

Crossman, AR ;

Brotchie, JM ;

Michel, A ;

Grimée, R ;

Klitgaard, H .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 485 (1-3) :159-164

[2] Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease [J].

Hill, MP ;

Ravenscroft, P ;

Bezard, E ;

Crossman, AR ;

Brotchie, JM ;

Michel, A ;

Grimée, R ;

Klitgaard, H .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (01) :386-394

[3] Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset [J].

Hill, MP ;

Bezard, E ;

McGuire, SG ;

Crossman, AR ;

Brotchie, JM ;

Michel, A ;

Grimée, R ;

Klitgaard, H .

MOVEMENT DISORDERS, 2003, 18 (11) :1301-1305

[4] The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam [J].

Lynch, BA ;

Lambeng, N ;

Nocka, K ;

Kensel-Hammes, P ;

Bajjalieh, SM ;

Matagne, A ;

Fuks, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (26) :9861-9866

[5]

Margineanu DG, 2000, PHARMACOL RES, V42, P281

[6] The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents [J].

Rigo, JM ;

Hans, G ;

Nguyen, L ;

Rocher, V ;

Belachew, S ;

Malgrange, B ;

Leprince, P ;

Moonen, G ;

Selak, I ;

Matagne, A ;

Klitgaard, H .

BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (05) :659-672

[7] How common are complications of Parkinson's disease? [J].

Schrag, A ;

Ben-Shlomo, Y ;

Quinn, N .

JOURNAL OF NEUROLOGY, 2002, 249 (04) :419-423

← 1 →